Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study

BACKGROUND: Novel agents such as proteasome inhibitors have been developed for several years to treat multiple myeloma. Although multiple myeloma is a low-risk disease for developing tumor lysis syndrome (TLS), treatment with these novel therapies might increase TLS risk. Previous studies, mostly ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Kondo, Masahiro, Hotta, Yuji, Yamauchi, Karen, Sanagawa, Akimasa, Komatsu, Hirokazu, Iida, Shinsuke, Kimura, Kazunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672870/
https://www.ncbi.nlm.nih.gov/pubmed/33203424
http://dx.doi.org/10.1186/s12885-020-07592-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672870/
https://www.ncbi.nlm.nih.gov/pubmed/33203424
http://dx.doi.org/10.1186/s12885-020-07592-9

Ejemplares similares